

05/21/99  
JC652 U.S. PTO

By Express Mail # 157 · May 21, 1999

JC525 U.S. PTO  
09/31/6624  
05/21/99

Attorney Docket No.: **4493-19CIP**

*Check box if applicable:*  
 **DUPLICATE**

## **UTILITY PATENT APPLICATION TRANSMITTAL**

*Submit an original and a duplicate for fee processing*

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Assistant Commissioner for Patents  
BOX PATENT APPLICATION  
Washington, DC 20231

Sir:

**THIS APPLICATION IS A [ ] CONTINUATION [ ] DIVISIONAL [x] CONTINUATION-IN-PART OF U.S. PATENT APPLICATION SERIAL NO. 08/838,073 WHICH WAS FILED April 15, 1997.**

Transmitted herewith for filing is the utility patent application of:

Inventor(s): Shalom Z. Hirschman

For: A Method For Treating Autoimmune Diseases

Enclosed are:

1. Specification (21 pp.), Claims 1 to 4 (1 p.) & Abstract (1 p.)
2. Executed Declaration and Power of Attorney (3 pp.)
3. Seven (7) sheet(s) of drawing(s) (Figs. 1A to 5)
4. Assignment of the invention to **Advanced Viral Research Corp.**
5. Recordation Cover Sheet (PTO-1595)
6. Check for **\$40.00** for Assignment Recording Fee
7. Copy of Verified Statement to Establish Small Entity Status from prior application. Statement filed in prior application and status still proper and desired.
8. Information Disclosure Statement
9. PTO Form 1449 with copies
10. A Filing Fee Calculation Sheet is attached hereto.

Please charge my Deposit Account No. 03-2412 in the amount of \$. A duplicate copy of this sheet is enclosed.

A check in the amount of \$ 380.00 to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this application or credit any overpayment to Deposit Acct. No. 03-2412.

Any additional filing fees required under 37 CFR 1.16 not otherwise paid by check.

Any patent appl. processing fees under 37 CFR 1.17

The issue fee set in 37 CFR 1.18 at 3 months from mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b) provided the fee has not already been paid by check.

Any filing fees under 37 CFR 1.16 for presentation of extra claims.

**Incorporation By Reference** (useable if submitting copy of declaration from prior application -- for continuation/divisional applications only):

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

Amend the specification by inserting before the first line the sentence (entire genealogy should be set forth):

"This is a  continuation,  division of application Serial No. 08/838,073, filed April 15, 1997 which is a ."

Priority is claimed for this invention and application, corresponding applications having been filed in \_ on , No. , respectively.

- a. Certified copies of the priority document(s) is (are) already of record in U.S. Application Serial No. 08/838,073, filed April 15, 1997, receipt of which has been acknowledged by the US PTO on in Paper No. .
- b. The certified priority document(s) is (are) enclosed herewith for filing in this continuing application.


[x] A Petition for Extension of Time in the parent application is enclosed so that the parent application will be pending as of the time this paper is filed.

The undersigned declares that the copy of the application papers (Specification, Claims, Abstract, Declaration and Power Of Attorney, and drawings and ) filed herewith are true copies of those originally filed in the U.S. Patent Office for Application Serial No. 08/838,073.

[X] The undersigned declares that all statements made herein of his or her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By:

  
Myron Cohen, Reg. No. 17,358

Dated: May 21, 1999

551 Fifth Avenue, Suite 1210  
New York, New York 10176  
Tel. (212) 687-2770

By Express Mail # EL370001434US

**APPLICATION FOR UNITED STATES  
LETTERS PATENT**

**A METHOD FOR TREATING AUTOIMMUNE DISEASES**

Inventor(s):

**Shalom Z. Hirschman**

**CROSS REFRENCE AND RELATED APPLICATION**

This is a continuation-in-part of application Serial Number 08/838,073 filed on April 15, 1997, entitled "A Method For Treating Autoimmune Diseases", now abandoned. Application Serial Number 08/838,073 is herein incorporated by reference in its entirety.

## **BACKGROUND OF THE INVENTION**

### **1. Field of the Invention**

The present invention relates to a method for using Product R as hereinafter defined to treat patients having rheumatoid arthritis.

### **5 2. Description of the Related Art**

Autoimmune diseases in mammals can generally be classified in one of two different categories: cell-mediated disease (i.e. T-cell) or antibody-mediated disorders. Non-limiting examples of cell-mediated autoimmune diseases include multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis, diabetes mellitus (Juvenile onset diabetes) and autoimmune uveoretinitis. Antibody-mediated autoimmune disorders include myasthenia gravis and systemic lupus erythematosus (or SLE).

Diseases with autoimmune features affect well over 5 percent of individuals at some time in their life. A large group of disparate autoimmune diseases are characterized by an often intense, sustained and injurious immune response apparently directed to a self-antigen. Autoimmunity is not a generalized state, but rather each disease reflects a highly specific pattern of recognition of different self structures and likely reflects equally distinct immune recognition events. These disorders vary from relatively mild conditions to those that virulently attack critical cells and organs of the body.

Autoimmune diseases may be classified as organ specific or non-organ specific depending on whether the response is primarily against either antigens localized to particular organs or widespread antigens. In organ specific diseases typified by Hashimoto's thyroiditis,

lesions are restricted because the antigen in the organ acts as a target for immunological attack. In non-organ specific disease typified by systemic lupus erythematosus (SLE), complexes formed with the antigens involved are deposited systemically, particularly in the kidney, joints and skin, so giving rise to the more disseminated features of the disease.

5 Systemic lupus erythematosus (SLE) is an inflammatory, multisystem disease characterized clinically as a relapsing disease of acute or insidious onset that may involve any organ in the body. Clinically, symptoms are due to disease affecting the skin, kidneys, serosal membranes, joints and heart. Anatomically, all sites have in common vascular lesions with fibrinoid deposits and immunologically, the disease involves antibodies of autoimmune origin, especially antinuclear antibodies (ANA). The ANA are directed against both DNA and RNA. Autoantibody development appears to be multifactorial in origin, involving genetic, hormonal, immunologic and environmental factors.

10  
15

20

Rheumatoid arthritis is a systemic, chronic, inflammatory disease that affects principally the joints and sometimes many other organs and tissues throughout the body. The disease is characterized by a nonsuppurative proliferative synovitis, which in time leads to the destruction of articular cartilage and progressive disabling arthritis. The disease is caused by persistent and self-perpetuating inflammation resulting from immunologic processes taking place in the joints. As is the case with most autoimmune diseases, the trigger that initiates the immune reaction remains unidentified. Both humoral and cell mediated immune responses are involved in the pathogenesis of rheumatoid arthritis. The majority of patients have elevated levels of serum

immunoglobulins and essentially all patients have an antibody called rheumatoid factor (RF) directed against a component of another antibody class.

Multiple sclerosis is another disease that is thought to be caused by autoimmune mechanisms. The cause of multiple sclerosis is unknown but seems to be multifactorial. 5 Susceptibility or resistance may be genetically determined; something in the environment interacts with the human host at the proper age to cause biochemical and structural lesions in the central nervous system. The systemic immune response and the response of the central nervous system become involved. Although the cause and pathogenesis of multiple sclerosis are unknown, it is widely believed that immune abnormalities are somehow related to the disease. Three possible mechanisms have been postulated: infection, autoimmunity, and a combination of the two. Suppression or modulation of the immune responses may be the key.

Myasthenia gravis is an autoimmune disorder caused by antibodies directed against the acetylcholine receptor of skeletal muscle. Present information indicates at least three mechanisms whereby acetylcholine receptor antibody may interfere with neuromuscular transmission and thus induce myasthenia gravis. Acetylcholine receptor antibody may interfere (directly or indirectly) with acetylcholine receptor function. In both experimental allergic myasthenia gravis and human myasthenia gravis, the extent of acetylcholine receptor loss parallels the clinical severity of the disease, suggesting that acetylcholine receptor antibody-induced acceleration of acetylcholine receptor degradation is important in the development of myasthenia gravis. Complement-mediated 15 destruction of the postsynaptic region is the third possible cause. Other disorders, especially those presumed to be autoimmune in origin, can occur in association with myasthenia gravis. Thyroid 20

disease, rheumatoid arthritis, systemic lupus erythematosus, and pernicious anemia all occur more commonly with myasthenia gravis than would be expected by chance.

Implication of viruses in autoimmunity has been supported by findings that autoimmune responses are induced, accelerate or enhanced concomitant with infection by a wide variety of human DNA and RNA viruses. Using an investigative approach that focuses on one potential mechanism where microbes cause autoimmunity, or molecular mimicry, a number of etiologic agents have been identified as potential causes of autoimmune disease.

Certain viruses have a mitogenic effect on unique lymphocyte subsets and hence act as polyclonal activators. Viruses can also infect lymphocytes and macrophage and directly or through their proteins cause release of lymphokines and manikines. These molecules can modulate immune responses in a variety of ways, including as growth or differentiation factors or by regulating MHC class I and/or class II expression on cells. Finally, microbial agents share determinants with host self proteins. In this instance, an immune response mounted by the host against a specific determinant of the infecting agent may cross-react with the mimic (shared) host sequence, leading to autoimmunity and, in some cases, tissue injury and disease.

The current treatments for both categories of autoimmune diseases involve administration of drugs which non-specifically suppress the immune response. Examples of such drugs are methotrexate, cyclophosphamide, Imuran (azathioprine) and cyclosporin A., steroid compounds such as prednisone and methylprednisilone are also employed in many instances. These drugs have limited efficacy against both cell- and antibody-mediated autoimmune diseases. Use of such drugs is limited by virtue of their toxic side effects and also because they induce

"global" immunosuppression in a patient receiving prolonged treatment with the drug, e.g. the normal protective immune response to pathogenic microorganisms is downregulated thereby increasing the risk of infections caused by these pathogens. A further drawback is that there is an increased risk that malignancies will develop in patients receiving prolonged global immunosuppression.

5

Reticulose<sup>1</sup> emerged as an antiviral product in the 1930's. While it was originally believed to be a product composed of peptone, peptides and nucleic acids, the precise composition remains unidentified. Nevertheless, Reticulose has demonstrated an ability to inhibit rapidly the course of several viral diseases. It is nontoxic, miscible with tissue fluids and blood sera and free from anaphylactogenic properties. Product R is a refinement of Reticulose prepared by an improved manufacturing process. It is a peptide nucleic acid preparation with defined composition.

Insofar as the applicant knows, Product R has never been used, nor suggested for treating autoimmune diseases.

---

<sup>1</sup> The agent was known under the trademark "Reticulose", a trademark of Advance Viral Research.

## SUMMARY OF THE INVENTION

An object of this invention therefore is to provide a method for treating a patient having autoimmune diseases by administering parenterally an effective treatment amount of Product R, a peptide-nucleic acid preparation, to the patient.

5 Product R is particularly useful in treating patients identified as having autoimmune disease rheumatoid arthritis.

Specifically, Product R is administered parenterally to the patients in a range from about 2.5 microliter to about 40 microliter per kilogram of the patient's body weight per day in a sterile injectable formulation. Prednisone is co-administered with Product R to the patients orally in a range from about 0.065 to about 1.35 milligram per kilogram of the patient's body weight per day.

Other objects and features of the present invention will become apparent from the following detailed description considered in conjunction with the accompanying drawings. It is to be understood, however, that the drawings are designed solely for purposes of illustration and not as a definition of the limits of the invention, for which reference should be made to the appended claims.

20 The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of the disclosure. For a better understanding of the invention, its operating advantages, and specific objects attained by its use, reference should be had to the drawing and descriptive matter in which there are illustrated and described preferred embodiments of the invention.

**BRIEF DESCRIPTION OF THE DRAWINGS**

In the drawings:

Figure 1A shows the reduction of spontaneous pain resulting from the treatment with Product R.

5 Figure 1B shows the reduction of the applied pressure pain resulting from the treatment with Product R.

Figure 1C shows the reduction of the movement pain resulting from the treatment with Product R.

10 Figure 2 shows the reduction of tumefaction of soft tissues resulting from the treatment with Product R..

Figure 3 shows the reduction of morning stiffness resulting from Product R treatment.

Figure 4 shows the mobility of the most affected joints before and after the treatment with Product R.

15 Figure 5 shows the improvements of various activities that were hindered by rheumatoid arthritis.

**DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS**

As used herein, Product R is the product produced according to either of the following methods.

**Method I For Preparing Product R**

5 Suspend about 35.0 g of casein, about 17.1 g of beef peptone, about 22.0 g of nucleic acid (RNA), about 3.25 g bovine serum albumin in about 2.5 liters of water for injection USP at about 3 to 7 °C in a suitable container and gently stir until all the ingredients have been properly wet. Carefully add while stirring about 16.5 g of sodium hydroxide (reagent grade ACS) and continue stirring until sodium hydroxide completely dissolved. Autoclave at about 9 lbs pressure and 200 - 230 °F for a period of time until RNA is completely digested, for example, about 4 hours. At the end of the period, the autoclave is stopped and the reaction flask and contents are permitted to slowly cool to ambient temperature. Then cool for at least six hours at about 3-8 °C. The resulting solution is filtered through 2 micron and 0.45 micron filters using inert gas such as nitrogen or argon at low pressure (1-6 psi). In a similar manner the solution is filtered again through 0.2 micron pyrogen retention filters. The resulting filtrate is sampled and assayed for total nitrogen. A calculation is then performed to determine the quantity of cooled water for injection to be added to the filtrate to yield a diluted filtrate with a nitrogen content between about 165-210 mg/ml, the final volume is approximately 5 liters. The pH is then adjusted with either concentrated HCl (reagent grade ACS) or 1.0 normal NaOH to about 7.3 - 7.6 range.

10 20 The diluted solution is then filtered again through 0.2 micron filters with inert gas at low pressure. The final filtrate is then filled and sealed into 2 ml glass ampules while in an inert gas

atmosphere. The ampules are collected and autoclave for final sterilization at 240 °F and 20 to 30 pounds pressure for about 30 minutes. Following the sterilization cycle, the ampules with Product R are cooled and washed.

5 All quantities are subject to plus or minus 2.5% variation for pH, volume, and analytical adjustments.

### **Method II For Preparing Product R**

10 Suspend about 35.0 g of casein, about 17.1 g of beef peptone, about 22.0 g of nucleic acid (RNA), about 3.25 g bovine serum albumin in about 2.5 liters of water for injection USP at about 3 to 7 °C in a suitable container and gently stir until all the ingredients have been properly wet. Slowly add while stirring about 11.75 ml of hydrochloric acid (reagent grade ACS) and continue stirring until hydrochloric acid is completely dissolved. Autoclave at about 9 lbs pressure and 200 - 230 °F for a period of time until RNA is completely digested, for example, about 4 hours. At the end of the period, the autoclave is stopped and the reaction flask and contents are permitted to slowly cool to ambient temperature. Then cool for at least six hours at about 3-8 °C. The resulting solution is filtered through 2 micron and 0.45 micron filters using inert gas such as nitrogen or argon at low pressure (1-6 psi). In a similar manner the solution is filtered again through 0.2 micron pyrogen retention filters. The resulting filtrate is sampled and assayed for total nitrogen. A calculation is then performed to determine the quantity of cooled water for injection to be added to the filtrate to yield a diluted filtrate with a nitrogen content 15 between about 165-210 mg/ml, the final volume is approximately 5 liters. The ph is then adjusted with either concentrated HCL (reagent grade ACS) or 35% (w/v) of NaOH to about 7.3 - 7.6

range. The diluted solution is then filtered again through 0.2 micr on filters with inert gas at low pressure. The final filtrate is then filled and sealed into 2 ml glass ampules while in an inert gas atmosphere. The ampules are collected and autoclave for final sterilization at 240 °F and 20 to 30 pounds pressure for about 30 minutes. Following the sterilization cycle, the ampules with Product

5 R are cooled and washed.

All quantities are subject to plus or minus 2.5% variation for pH, volume, and analytical adjustments.

Product R may administered alone or together with an autoimmune disease treatment agent. When administered to the patients, Product R may be applied parenterally, the autoimmune disease treatment agent, e.g. prednisone may be administered orally. The combination of Product R and prednisone may be applied either simultaneously or in alternation.

For the above autoimmune diseases, a suitable effective dose of Product R is in the range from about 2.5 microliter to about 40 microliter per kilogram of body weight per day, preferably in the range of about 5 microliter to about 25 microliter per kilogram of body weight per day. Most preferably Product R is administered in an amount of about 7.5 microliter per kilogram of body weight per day. The desired dose may be administered as two, three or more sub-doses at appropriate intervals, generally equally spread in time, throughout the day. Preferably, however, the full daily dose is administered in one administration.

20 Product R may be administered by any suitable injection route including, but not limited to intravenously, intraperitoneal, subcutaneously, intramuscularly, and intradermally, etc.

The presently preferred route of administration is intramuscularly. It will be appreciated that the preferred route may vary with, for example, the condition and age of the recipient.

While it is possible for Product R to be administered as part of a pharmaceutical formulation, it is preferable to present it alone, although it may be administered at about the same time as one or more other pharmaceuticals are independently administered. If Product R is administered as part of a pharmaceutical formulation, the formulations of the present invention comprise at least one administered ingredient, as above defined, together with one or more acceptable carriers thereof and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Preferably, Product R constitutes at least about 90% of such formulation by.

The formulations may conveniently be presented in unit-dose or multi-dose containers, e.g. sealed ampules and vials.

Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an appropriate fraction of the administered ingredient.

Prednisone is co-administered with Product R to provide a combined therapy in treating autoimmune diseases. While it is possible for the active ingredients of prednisone to be administered alone, it is preferable to present them as pharmaceutical formulations. The formulations comprise at least one active ingredient, together with one or more acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the

sense of being compatible with the other ingredients of the formulation and not deleterious to the patient thereof.

The formulations for prednisone includes those suitable for oral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers of finely divided solid carriers or both, and then, if necessary, shaping the products.

For oral administration, prednisone is calculated as the free base of about 0.065 to 1.35 milligram per kilogram, preferably 0.25 to 0.8 milligram per kilogram, of the patient's body weight per day, and is preferably used in a unit dosage form, and administered a few times daily in the amount of 1 to 50 milligram per unit dose. Dosage of prednisone should be individualized according to the severity of the disease and the response of the patient.

It should be understood that Product R may also be co-administered with other anti-autoimmune disease agents such as methotrexate, cyclophosphamide, imuran and cyclosporin A, etc. The dose of other anti-autoimmune disease agents to be co-administered with Product R can be readily determined by those skilled in the art, based on the usual patient symptoms, and severity of the diseases.

A clinical trial to assess the efficacy of Product R in patients suffering from rheumatoid arthritis (RA) has been conducted under a protocol designed by applicant. In this

clinical study, twenty-seven female patients ranging in age from 29 to 50 years old, suffering from mild to moderately severe RA for no longer than two years were treated with Product R for a total of 90 days. These patients had been previously treated with Aspirin and/or Paracetamol and/or Arrumalon. Product R was injected subcutaneously at a dose of 1 ml twice per day for 15 days and 1 ml once a day for 75 days. One additional patient, 44 years old, afflicted with severe RA manifested as decrease in articular space, osteopenia and subchondral sclerosis, who was previously treated with gold salts but discontinued due to toxic effects, was injected subcutaneously with Product R at a dose of 2 ml once per day for the first three days followed by 1 ml once per day for 12 months. Two other patients who had suffered from RA for seven and three years respectively were injected subcutaneously with 2 ml of Product R every other day for 15 days, 2 ml every other day for 15 more days and for the next year they were given a maintenance dose of 1 ml a day for 5 consecutive days every 4 months.

No major or minor side effects were observed or reported. Only one patient reported, on day 90, a mild reaction at the site of injection that lasted two days and resolved by itself.

The improvement of rheumatoid arthritis were determined according to measurements such as pain, tumefaction of soft tissues, morning stiffness, mobility of the most affected joint, the size of the most affected joint and some laboratory tests.

Figure 1A shows the reduction of spontaneous pain resulted from the treatment with Product R. Prior to the treatment, of twenty-seven patients, seven reported no pain, eight reported slight pain, and twelve reported moderate pain, which are represented by the shaded

bars. By day thirty of the treatment, five patients reported moderate pain and twelve patients reported slight pain. By day sixty, eleven patients had slight pain. By day ninety, only 5 patients still reported slight pain. The severe RA patient was monitored on days 0, 15, 30 and 45 of the treatment. By day 45, she still experienced moderate spontaneous pain.

5       Figure 1B shows the reduction of the pain produced by applied pressure. All twenty eight patients including the severe RA patient reported moderate (fifteen patients) to severe (thirteen patient) pain before the treatment. By day thirty of the treatment, eleven reported slight pain, fifteen moderate pain and two severe pain. By day sixty, fifteen patients had slight pain and thirteen reported moderate pain. By day ninety, one patient had no pain, twenty five slight pain and two moderate pain.

10       Figure 1C shows the reduction of the pain produced by movements. All 28 patients reported pain produced by movement before the including 11 suffering from slight pain, 16 moderate pain and one severe pain (the severe RA patient). By day 30 of the treatment, 15 reported slight pain, 12 had moderate pain and one had severe pain. By day 60, 6 had no pain, 17 had slight pain and 5 had moderate pain. By day 90, 11 had no pain, 16 had slight pain and one had moderate pain.

15       Figure 2 shows the reduction of tumefaction of soft tissues. All 28 patients had some degree of tumefaction (swell) of soft tissue before the treatment including 10 slight, 17 moderate and one severe tumefaction. By day 30, 5 patients having moderate tumefaction reported slight tumefaction. By day 60, seven more patients changed form moderate to slight

tumefaction. By day 90, five patients had complete disappearance of tumefaction, 21 had slight tumefaction and two remained with moderate tumefaction.

Figure 3 shows the reduction of morning stiffness resulting from Product R treatment. Of the 28 patients, 22 had morning stiffness, which in 15 patients lasted 15 minutes or more before the Product R treatment. By day 30, one of the 22 patients reported no morning stiffness, and seven reported a reduction of morning stiffness. By day 60, an additional five patients had no morning stiffness and a total of 15 patients had a reduction of morning stiffness. By day 90, a total of 15 patients had no stiffness as compared to 6 before the treatment. 12 patients remained with morning stiffness of 15 minutes or less. One patient remained with morning stiffness of more than 15 minutes.

Figure 4 shows the mobility of the most affected joints before and after the treatment with Product R. Mobility was measured by degrees of flexion and extension of the joint. All 28 patients had impaired mobility of the joints. Most patients had affected joints in hands and three patients included impaired feet joints. Flexion ranged from 30 to 50 degrees with the remainder ranging from 80 to 110 degrees. In most cases it took 60 days to see a marked improvement. At that point the improvement became exponential.

As a measurement of inflammation, the circumference in millimeters of the most affected joint was recorded. All 27 patients experienced a marked decrease in joint sizes. These decreases were visible in all cases by day 30. The reduction of the circumference of the most affected joint is also shown in Figure 4.

Figure 5 shows the improvements of various activities that were hindered by RA.

These activities include:

Strenuous exercise:

Before Product R therapy, all 27 patients were limited in their ability to perform strenuous exercises such as running, lifting heavy objects or participation in exhausting sports. 16 patients considered themselves extremely limited and 12 moderately limited. By day 90 of the therapy, two patients reported not being limited at all, 17 were moderately limited and eight still were very limited in their ability to perform strenuous exercise.

Moderate exercise:

19 patients out of the 27 patients considered themselves to be moderately limited in their ability to perform moderate exercises such as moving a table, pushing a vacuum cleaner, bowling or playing golf. By day 90, only six patients were limited in performing moderate exercises.

Job/Housework:

27 patients had problems performing their job or housework at the beginning of the study. By day 90, only seven still had problems but to a much lower degree in all cases.

Social activities:

27 patients had some disability in performing social activities due to their illness at the beginning of the treatment. By day 90, only six still reported problems but all improvements from the pretherapy state.

Emotional problems:

21 patients reported emotional problems due to their disease at the start of the therapy. By day 90, only two still reported emotional problems and both reported improvement resulting from Product R therapy.

In addition to the above observations, all patients' blood samples were collected 5 and subjected to standard clinical laboratory tests which are designed for diagnosis and treatment of rheumatoid arthritis and performed routinely by persons of ordinary skill in the art. The results of these tests are summarized in Table I.

TABLE I

Patient	Hb (mg/ml)		ESR (mm)		Latex Fixation Test (IU/ml)		Rose Ragan Test (IU/ml)	
	Day 0	Day 90	Day 0	Day 90	Day 0	Day 90	Day 0	Day 90
1	14.4	14.1	38	26	+	30	+	30
2	13.6	14.2	32	26	+	>40	+	30
3	14.3	13.8	27	20	++	60	+	30
4	14.0	13.8	29	19	++	60	+	30
5	13.6	14.3	32	20	++	60	+	30
6	14.2	13.8	29	18	++	60	++	60
7	12.0	13.3	32	19	++	60	+	30
8	14.0	13.8	27	16	+	30	+	30
9	13.4	14.0	36	22	+++	120	+	30
10	13.8	14.3	29	15	++	60	+	30
11	14.0	13.8	28	19	++	60	+	30
12	13.5	14.3	26	14	++	60	+	30
13	13.6	14.3	34	19	+++	120	+	30
14	12.0	13.0	27	17	+++	120	+	30
15	11.3	12.7	20	13	+	30	-	
16	13.8	14.4	26	18	++	60	+	30
17	12.7	13.6	27	14	+++	120	+	30
18	12.6	13.8	29	18	++	60	+	30
19	13.7	14.8	31	17	+	30	+	30
20	13.6	14.2	27	16	+	30	+	30
21	12.6	13.9	25	14	+++	120	+	30
22	13.4	13.9	31	19	++	60	+	30
23	12.8	14.2	25	14	++	60	+	30
24	14.0	13.7	27	15	+++	120	+	30
25	14.4	14.8	22	16	++	60	+	30

26	13.9	14.1	31	19	+++	120	+	30	+++	128	++	32
27	13.7	14.3	23	17	++	60	+	30	++	32	+	8

20 patients out of 27 had slight increases of hemaglobulin (Hb) values after 90 days of the treatment as compared with pretreatment values. The rest either remained the same or had slight decreases.

5 All 27 patients had lower values of erythrocyte sedimentation rate (ESR) on day 90 compared with their corresponding pretreatment values. The average decrease was 10.74 mm with the maximum being 15 mm and the minimum 6 mm.

10 All 27 patients had positive latex fixation tests before the treatment. On day 90 after the start of the treatment, of the 27 patients, 22 had decreased values compared with their corresponding pretreatment values. The other five remained the same: one moderately positive (++, 60 IU/ml) and four low positives (+, 30 IU/ml). Only one patient, who had a low positive value to start with (+, 30 IU/ml), became negative to the latex fixation test. The rest, whose values ranged from 30 to 120 IU/ml all became low positives (+, 30 IU/ml).

15 All 27 patients had positive Rose Ragan tests before the treatment. None of them became negative but 24 patients showed decreases of the positive values and three remained at the minimum positive value (+, 8 IU/ml) with which they started. 21 patients lowered their values to 8 IU/ml including eight patients who started with high positive values of 128 IU/ml. Three patients lowered their values to 32 IU/ml, two of whom started with 128 IU/ml and one had a very high value of 512 IU/ml before the treatment.

5

Thus, while there have been shown and described and pointed out fundamental novel features of the invention as applied to preferred embodiments thereof, it will be understood that various omissions and substitutions and changes in the form and details of the operation illustrated may be made by those skilled in the art without departing from the spirit of the invention. For example, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the invention. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.

The invention is not limited by the embodiments described above which are presented as examples only but can be modified in various ways within the scope of protection defined by the appended patent claims.

CLAIMS

I claim:

1           1. A method of ameliorating a symptom of rheumatoid arthritis in a patient  
2 suffering from rheumatoid arthritis, comprising parenterally administering to said patient an  
3 effective symptom ameliorating amount of Product R in a range from about 2.5 microliter to  
4 about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable  
5 formulation.

1           2. The method of claim 1 wherein said Product R is administered in a range  
2 from about 5 microliters to about 25 microliters per kilogram of body weight per day.

1           3. The method of claim 1 wherein said Product R is administered in  
2 amount of about 7.5 microliters per kilogram of body weight per day.

1           4. A method of ameliorating a symptom of rheumatoid arthritis in a  
2 patient suffering from rheumatoid arthritis, comprising the steps of:

3           a. parenterally administering Product R to said patient an effective symptom  
4           ameliorating amount of about 1 ml twice per day in a pharmaceutically  
5           acceptable formulation for about 15 days; and

6           b. Parenterally administering Product R to said patient an effective symptom  
7           ameliorating amount of about 1 ml once per day in a pharmaceutically  
8           acceptable formulation for about 75 days after step a.

## ABSTRACT OF THE DISCLOSURE

A method of treating patients having rheumatoid arthritis by administering Product R, a peptide-nucleic acid preparation, is disclosed.

Fig. 1A

### Spontaneous Pain




Fig. 1B

### Applied Pressure Pain




Fig. 1C

### Movement Pain




Fig. 2

## Tumefaction of Soft Tissue





Figure 3






Figure 4





Figure 5



## DECLARATION AND POWER OF ATTORNEY FOR CIP PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

### A METHOD FOR TREATING AUTOIMMUNE DISEASES

the specification of which is attached hereto unless the following box is checked:

I hereby state that this application in part discloses and claims subject material disclosed in my earlier-filed pending application Serial No. **08/838,073** filed **April 15, 1997**.

I hereby state that I reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56.

I also acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37 CFR 1.63(d), which occurred between the filing date of the prior application and the filing date of the continuation-in-part application, if this is a continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

**Prior Foreign Application:**

**Country:**

**Appln. No.:**

**Filed:**

**Priority Not Claimed:**  [ x ]

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

**Application No.:**

**Filing Date:**

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

**Appln No.: 08/838,073      Filing Date: April 15, 1997 Status: pending**

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

MYRON COHEN, Reg. No. 17,358; THOMAS C. PONTANI, Reg. No. 29,763; LANCE J. LIEBERMAN, Reg. No. 28,437; MARTIN B. PAVANE, Reg. No. 28,337; MICHAEL C. STUART, Reg. No. 35,698; KLAUS P. STOFFEL, Reg. No. 31,668; EDWARD M. WEISZ, Reg. No. 37,257; CHI K. ENG, Reg. No. 38,870; JULIA S. KIM, Reg. No. 36,567; VINCENT M. FAZZARI, Reg. No. 26,879; ALFRED W. FROEBRICH, Reg. No. 38,887; ANDRES N. MADRID, Reg. No. 40,710; KENT H. CHENG, Reg. No. 33,849; GEORGE WANG, Reg. No. 41,419; JEFFREY M. NAVON, Reg. No. 32,711 and JOHN G. TUTUNJIAN, Reg. No. 39,405.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Address all telephone calls to Myron Cohen, Esq. at telephone No. (212) 687-2770.

Address all correspondence to:

Myron Cohen, Esq.  
Cohen, Pontani, Lieberman & Pavane  
551 Fifth Avenue, Suite 1210  
New York, New York 10176

**Full Name of Sole or First Inventor: Shalom Z. Hirschman**

Inventor's signature: Shalom Z. Hirschman

Dated: May 14, 1999  
Month/Day/Year

Residence: **5420 Blackstone Avenue**  
**Riverdale, NY 10471**

Citizenship: **U.S.**

Post Office Address: **5420 Blackstone Avenue**  
**Riverdale, NY 10471**